Vincerx Pharma

30 articles with Vincerx Pharma

• Vincerx Pharma Announces First Patient Dosed in Phase 1b Study of VIP152 in MYC-Driven Relapsed or Refractory Aggressive Lymphomas and Advanced Solid Tumors

  6/3/2021

  First patient dosed by Vincerx marks significant milestone in Company’s development

• Vincerx Pharma to Participate in the Jefferies Virtual Healthcare Conference

  5/26/2021

  Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that Vincerx’s Chief Business Officer, Stuart Hwang, PhD, will present a corporate overview at the Jefferies Virtual Healthcare Conference, to be held June 1-4, 2021.

• Vincerx Pharma Reports First Quarter 2021 Financial Results and Provides a Corporate Update

  5/17/2021

  Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update.

• Vincerx Pharma Announces Completion of Public Warrant Redemption

  5/6/2021

  Vincerx Pharma, Inc., announced the completion of its redemption event with respect to its outstanding public warrants.

• Vincerx Pharma Announces FDA Clearance of IND for Phase 1b Study of VIP152 in Chronic Lymphocytic Leukemia and Richter Syndrome

  4/20/2021

  Dose escalation study in patients with CLL relapsed/refractory to venetoclax and BTK inhibitors on track to initiate in 2H2021 Vincerx’s second clinical program for potential best-in-class CDK9 inhibitor First patient in Phase 1b Study in MYC-driven R/R aggressive lymphomas and advanced solid tumors expected 2Q 2021

• Vincerx Pharma Presents Preclinical Data on VIP236, its Lead Small Molecule Drug Conjugate, at the American Association for Cancer Research Annual Meeting 2021

  4/10/2021

  Vincerx Pharma, Inc. is a biopharmaceutical company aspiring to address the unmet medical needs of cancer patients through paradigm-shifting therapeutics.

• Vincerx Pharma To Host Key Opinion Leader Webinar on Bioconjugation and CDK9 Inhibitors for the Treatment of Hematologic and Solid Tumors

  4/7/2021

  Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that it will be hosting a key opinion leader (KOL) meeting on bioconjugation and CDK9 inhibitors for the treatment of hematologic and solid tumors on Friday, April 16, 2021 at 12:00 PM ET.

• Vincerx Pharma Announces Redemption of Public Warrants

  4/5/2021

  Vincerx Pharma, Inc. (Nasdaq: VINC) (the “Company”), today announced that it will redeem all of its outstanding public warrants (the “Public Warrants”) to purchase shares of the Company’s common stock, $0.0001 par value per share (“Common Stock”), that were issued under the Warrant Agreement, dated as of March 5, 2020 (the “Warrant Agreement”)

• Vincerx Pharma Announces Formation of Scientific Advisory Board to Advance its Clinical Pipeline

  4/1/2021

  Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced the formation of its Scientific Advisory Board (SAB) composed of world leading academics and industry leaders in cancer research and therapeutics. John C. Byrd, M.D., will serve as Chairman of the SAB.

• Vincerx Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update

  3/23/2021

  Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the fourth quarter and full year, ended December 31, 2020, and provided a corporate update.